All companies
424B4Oct 9, 2026
SU
Sunshine Biopharma Inc
SBFMPublic
PublicUnited States(Nasdaq)Best valuation $1.84M1 market
Public listing
Listed· Nasdaq· Listing market: United StatesListing date
Not available
Offer price
Not available
Shares offered
Not available
Offering proceeds
Not available
Sources: SEC EDGAR, Nasdaq
IPO Calendar · NasdaqIPO
SBFMPrice
$2.23
24h
-5.11%
Valuation
$1.84M
24h volume
$51.96K
Type
IPO
IPO Calendar · updated 2h ago
Sunshine Biopharma Inc IPO public float & lock-up
Public float and locked shares extracted from Sunshine Biopharma Inc's SEC prospectus. Shares shown are eligible to trade — lock-up expiry does not mean holders have sold or will sell.
Total shares (FD)
15.22M
Public float
—
Locked
—
IPO raise
—
Next unlock
—
Needs review: Could not extract a detailed lock-up release schedule.
Financials
UnprofitableFrom SEC filings, latest FY ending Dec 31, 2025 · CIK 0001402328.
Revenue · +4.11% YoY
$36.31M
Net income
-$5.98M
Gross margin
33.76%
Cash
$21.83M
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $36.31M | $34.87M | $24.09M | $4.35M | $228.43K |
| Gross profit | $12.26M | $10.67M | $8.34M | $1.7M | $110.6K |
| Operating income | -$6.23M | -$5.81M | -$4.79M | -$27M | -$2.44M |
| Net income | -$5.98M | -$5.13M | -$4.51M | -$26.74M | -$12.44M |
| R&D expense | $604.31K | $933.9K | $1.86M | $811.86K | $672.21K |
| Cash & equivalents | — | — | — | $21.83M | $2.05M |
| Total assets | $30.08M | $30.56M | $27.35M | $29.24M | $2.2M |
| Total liabilities | $7.04M | $7.06M | $6.14M | $7.62M | $1.99M |
| Shareholders' equity | $23.04M | $23.5M | $21.21M | $21.63M | $211.66K |
About Sunshine Biopharma Inc
Sunshine Biopharma is a pharmaceutical company with generic prescription drugs, over-the-counter products, and proprietary drug-development programs.
What the company does
- Operates through subsidiaries including Nora Pharma, which markets generic prescription drugs in Canada.
- Develops or researches proprietary programs in therapeutic areas such as oncology and antivirals.
- Combines commercial pharmaceutical distribution with earlier-stage research and product-development activities.
Business profile
Sunshine Biopharma operates in pharmaceuticals, where regulatory approvals, product portfolio breadth, manufacturing and distribution quality, and clinical execution are central.
SEC IPO filings
FiledEDGAR filings resolved from SBFM / CIK 0001402328.
Nov 18, 2026Filed0001683168-26-008932
424B4PROSPECTUS
Oct 9, 2026Final prospectus0001683168-26-007757
Oct 7, 2026Effective9999999995-26-003179
S-1FORM S-1
Oct 2, 2026Filed0001683168-26-007581
Sep 24, 2026Confidential draft0001683168-26-007374
Sep 8, 2026Effective9999999995-26-002914
424B3FORM 424B3
Sep 8, 2026Final prospectus0001683168-26-007017
S-1FORM S-1
Aug 28, 2026Filed0001683168-26-006779
424B4PROSPECTUS
May 19, 2026Final prospectus0001683168-26-004098
May 18, 2026Effective9999999995-26-001691
CORRESPfilename1.htm
May 18, 2026SEC correspondence0001683168-26-004050
CORRESPfilename1.htm
May 18, 2026SEC correspondence0001683168-26-004049
Sunshine Biopharma Inc IPO — frequently asked questions
- When did Sunshine Biopharma Inc go public?
- Sunshine Biopharma Inc has already gone public and now trades publicly on Nasdaq under the ticker SBFM.
- Can I buy Sunshine Biopharma Inc stock?
- Yes — Sunshine Biopharma Inc is publicly traded on Nasdaq as SBFM. You can follow its live price, valuation and post-IPO performance above.
- What is Sunshine Biopharma Inc's valuation?
- Sunshine Biopharma Inc's most recent valuation tracked here is $1.84M, derived from live market prices.